Tempus Acquires Paige to Enhance Precision Medicine with AI

Tempus AI has acquired Paige, an AI company specializing in digital pathology. Paige has developed an FDA-cleared AI application for cancer detection and has amassed a dataset of almost 7 million digitized pathology slides. The acquisition expands Tempus' dataset and technical team, solidifying its position in digital pathology and enabling the advancement of drug discovery and development.

Tempus AI, Inc. (TEM), a leading technology company focused on personalized medicine, has acquired Paige, an AI company specializing in digital pathology. The acquisition strengthens Tempus' position in digital pathology and expands its dataset, enabling advancements in drug discovery and development.

Paige, an FDA-cleared AI application for cancer detection, has amassed a dataset of nearly 7 million digitized pathology slides. The acquisition will significantly enhance Tempus' dataset, providing more comprehensive data for its AI applications. Additionally, Paige's technical team will bolster Tempus' capabilities, further solidifying its position in digital pathology.

The acquisition aligns with Tempus' strategy to leverage AI and data analytics to personalize medicine. Tempus' AI platforms, Lens and Next, are already being used to analyze genomic data and provide clinical decision support tools. The integration of Paige's technology will enhance these capabilities, enabling Tempus to offer more advanced and accurate diagnostics.

Tempus has been rapidly expanding its partnerships across oncology and neuroscience. Recent collaborations include a multi-year agreement with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine to use Tempus' AI-powered Lens platform for Alzheimer’s research [2]. Additionally, Tempus has partnered with the Institute for Follicular Lymphoma Innovation to create a real-world, multimodal, deidentified FL data library in Lens, enabling AI-driven insights to accelerate follicular lymphoma treatment development [2].

In the past year, Tempus AI shares have surged 35.9%, outperforming the industry’s 21.4% growth and the S&P 500 composite’s 15.9% improvement [2]. Despite the strong performance, Tempus' stock currently carries a Zacks Rank #2 (Buy), indicating a positive outlook from financial analysts [2].

References:
[1] https://www.marketscreener.com/news/tempus-ai-insider-sold-shares-worth-3-075-600-according-to-a-recent-sec-filing-ce7c51dfdf80f523
[2] https://www.nasdaq.com/articles/strategic-partnerships-power-tempus-ais-healthcare-expansion